| Bioactivity | Catumaxomab, a trifunctional IgG2 antibody, is composed of mouse and rat heavy and light chains and binds to human EpCAM and human CD 3 receptors. The Fc region of Catumaxomab region has binding affinity for FcγR1 (CD 64), FcγRIIA (CD 32a), and FcγRIII (CD 16). Catumaxomab can be used for anti-tumor research, especially epithelial cancers[1][2]. |
| Invitro | Catumaxomab (0-5 ng/mL; 3-7 天) 以剂量依赖的方式强烈抑制与 PBMC 共培养的 FaDu 肿瘤球体的生长[2]. |
| Name | Catumaxomab |
| CAS | 509077-98-9 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Mansoor M. Amiji, et.al. Chapter Two - Innate and adaptive immunity in cancer. Cancer Immunology and Immunotherapy. Academic Press, 2022, Pages 19-61. [2]. Hirschhaeuser F, et.al. Efficacy of catumaxomab in tumor spheroid killing is mediated by its trifunctional mode of action. Cancer Immunol Immunother. 2010 Nov;59(11):1675-84. |